Clinical studies testing higher aromatase inhibitor doses have found no added benefit to lowering estrogens in women with obesity (78) or to breast cancer outcomes in general (79, 80), suggesting that the mechanisms of obesity-associated breast cancer progression and mortality are estrogen-independent. The gene discussed is CYP19A1; the disease is obesity due to melanocortin 4 receptor deficiency.